Thomas J. Lynch, Jr., MD, stepped down this week from his role as chairman and CEO of the MGPO to accept a senior leadership opportunity at Bristol-Myers Squibb. Effective March 16, Lynch became the executive vice president and chief scientific officer of the global biopharmaceutical company, leading its Research and Development enterprise.

The process of forming a search committee to identify a new CEO is under way. In the meantime, Greg Pauly, COO of the MGPO, will serve as interim CEO.

“While this news is sad for the MGPO and MGH – indeed for all of us who have worked with and learned from him – this new role offers Tom an important and highly visible platform to make a far-reaching difference on the health of patients around the world,” said Peter L. Slavin, MD, MGH president.

Lynch joined the MGH medical staff in 1993, after completing his residency in medicine at the MGH and a fellowship in medical oncology at Dana-Farber Cancer Institute. He then served as as chief of Hematology-Oncology at the MGH Cancer Center and director of the Center for Thoracic Cancers before accepting a role as director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven. He returned to lead the MGPO in September 2015.

Read more articles from the 03/17/17 Hotline issue.